BRD9 and acute myeloid leukemia: Significantly, various pieces of evidence have demonstrated that BRD9 knockdown effectively restrains the proliferation of human acute myeloid leukemia (AML), synovial sarcoma [22], and malignant rhabdoid tumor (MRT) [23].